A laboratory testing kit developed at the University of North Carolina Lineberger Comprehensive Cancer Center received approval from the U.S. Food and Drug Administration. Developed by Chuck Perou, PhD and professor of genetics and pathology, the testing kit estimates the risk of breast cancer relapse even in cases of anti-hormone treatment. According to the University of North Carolina at Chapel Hill, other scientists who worked with Perou include Dr. Joel Parker and Dr. Maggie Cheang at the University of North Carolina.
“This approval marks more than a decade of work with my fellow researchers and highlights the growing importance of genomic and genetic tests in the oncology clinic,” said Dr. Perou. “This test is the result of data coming from modern, cutting-edge genomic technologies, and thus it is exciting to see the bench to bedside story fulfilled.”
The University of North Carolina at Chapel Hill is a market rich with life science funding. In 2012, the NIH awarded the university $377.6 million in life science research funding. In addition to receiving NIH funding, the University of North Carolina at Chapel Hill also received $38.8 million in life science funding from the NSF in 2012. More NIH and NSF funding statistics, including departmental funding breakdowns and specific projects receiving life science research funding, can be found at the NIH and NSF websites.
University of North Carolina at Chapel Hill
Breast cancer research receives millions of dollars in funding from sources around the country every year. Earlier this month, the Breast Cancer Research Foundation announced that it will dedicate $45 million to breast cancer research. According to Yahoo Finance, this life science funding will be awarded in the form of grants to 207 doctors and scientists, upholding the foundation’s 20-year commitment to advance groundbreaking research in the field. Other life science research funding organizations also provide research funding for doctors and scientists studying breast cancer. According to the National Cancer Institute (NCI), the NCI awarded $602.7 million in breast cancer funding alone in 2012.
If you are a lab supplier interested in networking with researchers with available life science funding at the University of North Carolina at Chapel Hill, Biotechnology Calendar, Inc. invites you to attend our Chapel Hill BioResearch Product Faire™ Event. Last year, the Chapel Hill BioResearch Product Faire™ Event attracted 87 attendees. Of those who came, 37 were purchasing agents, professors and post docs, and 15 were lab managers. The attendees at this life science event came from 14 different research buildings and 25 departments across campus.
Biotechnology Calendar, Inc. is a full-service science research marketing and events-planning company that has been organizing life science events at top research institutions across the country for 20 years. If you are interested in marketing lab products to researchers with available life science funding at life science events closer to home, we encourage you to view our 2013 calendar of events. For more detailed funding statistics on the University of North Carolina at Chapel Hill, or to learn more about the Chapel Hill BioResearch Product Faire™ Event, click on the button below.